Glaukos Corp
$ 170.99
0.04%
06 Aug - close price
- Market Cap 10,082,124,000 USD
- Current Price $ 170.99
- High / Low $ 171.99 / 168.39
- Stock P/E N/A
- Book Value 11.60
- EPS -3.28
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.26 %
- 52 Week High 184.00
- 52 Week Low 73.16
About
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Analyst Target Price
$193.62
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-29 | 2026-02-17 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-11-04 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 |
| Reported EPS | -0.14 | -0.18 | -0.9 | -0.16 | -0.24 | -0.22 | -0.4 | -0.28 | -0.52 | -0.7 | -0.63 | -0.5 |
| Estimated EPS | -0.28 | -0.28 | -0.21 | -0.26 | -0.26 | -0.35 | -0.3885 | -0.48 | -0.51 | -0.57 | -0.55 | -0.55 |
| Surprise | 0.14 | 0.1 | -0.69 | 0.1 | 0.02 | 0.13 | -0.0115 | 0.2 | -0.01 | -0.13 | -0.08 | 0.05 |
| Surprise Percentage | 50% | 35.7143% | -328.5714% | 38.4615% | 7.6923% | 37.1429% | -2.9601% | 41.6667% | -1.9608% | -22.807% | -14.5455% | 9.0909% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GKOS
2026-08-04 20:11:33
Glaukos Corporation has completed patient enrollment in its U.S. pivotal clinical study for the PRESERFLO MicroShunt, a device designed to lower intraocular pressure in adult patients with primary open-angle glaucoma. The study aims to support a potential 510(k) clearance from the FDA, evaluating a 20% reduction in mean diurnal IOP from baseline. The PRESERFLO MicroShunt has already received regulatory approval in Canada and Australia and has demonstrated favorable outcomes compared to trabeculectomy in previous evaluations, including lower rates of adverse events.
2026-08-04 03:40:22
Glaukos presented its investor strategy focusing on interventional glaucoma to reduce reliance on topical drops, citing high non-compliance rates. Key products include iDose TR, a long-duration travoprost implant, and Epioxa, an FDA-cleared epithelium-on cross-linking therapy for keratoconus. The presentation highlighted clinical metrics for iDose TR and ongoing pipeline development for next-generation iDose devices.
2026-07-31 20:09:51
An insider at Glaukos Corporation (NYSE: GKOS), Leana Wen, plans to sell 525 vested shares of common stock with an aggregate market value of $88,005.75 around July 31, 2026. These shares are compensation from restricted stock that vested on May 30, 2025. Wen previously sold 1,700 shares on May 1, 2026, totaling $247,095.17.
2026-07-30 19:40:19
Glaukos Corporation (GKOS) has received a raised 12-month average price target of $193.62 from 13 analysts, up from $163.85. This new target implies a potential upside of approximately 20% from its July 29 closing price. The consensus rating for GKOS remains a "Buy" among 14 covering analysts.
2026-07-30 15:40:19
Stifel raised its price target on Glaukos Corporation (NYSE:GKOS) to $190 from $175, maintaining a Buy rating, based on positive surveys for iDose and Epioxa and a strong revenue outlook, projecting $1.0 billion or more in 2027. This follows Glaukos exceeding Q2 2026 earnings expectations with record net sales, leading other analysts like Needham and Truist Securities to also raise their price targets. Despite the stock's 72% surge, InvestingPro suggests the shares might be overvalued.
2026-07-30 11:11:25
Glaukos Corp (GKOS) stock recently reached a 52-week high of $161.67, with a year-to-date return of 34% and a 70.14% increase over the past year. Despite this strong performance, InvestingPro analysis indicates the stock may be overvalued relative to its Fair Value. The company also announced the completion of patient enrollment for its Phase 2 clinical study of GLK-321, and analysts from Stifel, Piper Sandler, and William Blair have reiterated ratings with varied price targets for its products like iDose and Epioxa.
